WuXi To Go Private In $33bn CEO-Backed Deal
This article was originally published in Scrip
Eight years after WuXi PharmaTech went public on the US stock market, the Shanghai-based clinical research organization (CRO) will become a private company again in a $3.3bn acquisition proposed by various private equity investors and WuXi executives, including chairman and CEO Ge Li.
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.